Stockscreener 앱 받기
12.87
2.30%
-0.1699
Rocket Pharmaceuticals Inc 주식(RCKT)의 최신 뉴스
Needham & Company LLC Reiterates Buy Rating for Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
Cantor Fitzgerald Reaffirms “Overweight” Rating for Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Earns Buy Rating from Chardan Capital - Defense World
Rocket Pharmaceuticals Advances Genetic Therapies Pipeline - TipRanks
Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst - AOL
Leerink Partners Issues Pessimistic Forecast for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price - MarketBeat
Cantor Fitzgerald Reiterates Overweight Rating for Rocket Pharmaceuticals (NASDAQ:RCKT) - MarketBeat
Rocket Pharmaceuticals' (RCKT) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Rocket Pharmaceuticals shares hold strong with Buy rating By Investing.com - Investing.com UK
First Turn Management LLC Purchases 60,317 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharma reports promising Phase 1 results for Danon disease therapy - Investing.com Australia
Rocket Pharma Stock Slips Despite New Long-Term Data On Phase-I Study; Retail Sentiment Slides - Asianet Newsable
Rocket Pharmaceuticals (NASDAQ:RCKT) Reaches New 52-Week LowHere's What Happened - MarketBeat
Rocket Pharma's Danon Disease Treatment Shows 5-Year Success in Phase 1 Trial | RCKT Stock News - StockTitan
Rocket Pharmaceuticals is Now Oversold (RCKT) - Nasdaq
When (RCKT) Moves Investors should Listen - Stock Traders Daily
Chardan Capital Has Strong Estimate for RCKT FY2024 Earnings - MarketBeat
RCKT stock touches 52-week low at $15.96 amid market challenges - Investing.com India
Rocket Pharmaceuticals' SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Rocket Pharma to Present Groundbreaking Danon Disease Gene Therapy Data at AHA 2024 | RCKT Stock News - StockTitan
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline In Focus - Barchart
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus - Yahoo Finance
Privium Fund Management B.V. Has $5.45 Million Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Analysts Set Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Price Target at $51.75 - MarketBeat
Wellington Management Group LLP's Strategic Acquisition in Rocke - GuruFocus.com
Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference - BioSpace
Rocket Pharmaceuticals' (RCKT) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
Rocket Pharmaceuticals: Q3 Earnings Snapshot - Houston Chronicle
Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress - Yahoo Finance
Investors Appear Satisfied With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Prospects As Shares Rocket 41% - Simply Wall St
Here's Why We're Watching Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Situation - Yahoo Finance
Harbor Capital Advisors Inc. Has $3.11 Million Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharmaceuticals executive sells $51,205 in common stock - Investing.com
Rocket Pharmaceuticals executive sells $51,205 in common stock By Investing.com - Investing.com UK
Long Term Trading Analysis for (RCKT) - Stock Traders Daily
(RCKT) Trading Report - Stock Traders Daily
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ - GlobeNewswire
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - India Shorts
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Down 5.3%Here's What Happened - MarketBeat
Fanconi Anemia Pipeline Forecast 2024: FDA Approvals, Therapies, and Leading Companies | Foresee Pharma, Rocket Pharma, John Diaz, Novartis, Sierra Oncology - The Globe and Mail
Scotiabank Initiates Coverage of Rocket Pharmaceuticals (RCKT) with Sector Outperform Recommendation - MSN
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Gap UpWhat's Next? - MarketBeat
Investors in cash trouble should check out Rocket Pharmaceuticals Inc (RCKT) - SETE News
Rocket Pharmaceuticals (NASDAQ:RCKT) Now Covered by Analysts at Scotiabank - MarketBeat
The Attractiveness of Investing In Rocket Pharmaceuticals Inc (RCKT) is Growing - Knox Daily
Rocket Pharmaceuticals Inc (RCKT)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Recent Insider Activity Could Benefit Pacific Biosciences of California Inc (PACB) - Knox Daily
Verisk Analytics Inc [VRSK] Investment Appeal on the Rise - Knox Daily
Rocket Pharmaceuticals Inc (RCKT)’s stock chart: A technical perspective - US Post News
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives $52.00 Consensus Target Price from Brokerages - MarketBeat
Trading (RCKT) With Integrated Risk Controls - Stock Traders Daily
0.42%
0.16%
자본화:
|
볼륨(24시간):